Kairos Pharma Signs Term Sheet to Acquire Two Clinical-Stage Lung Cancer Assets from Celyn Therapeutics
核心洞察
Kairos Pharma (搜索) has signed a term sheet to acquire CL-273 (搜索), a pan-EGFR (搜索) inhibitor, and CL-741 (搜索), a c-MET (搜索) inhibitor, from Celyn Therapeutics (搜索) to target the multi-billion dollar lung cancer market.
The acquisition aims to strengthen Kairos's strategy of overcoming drug resistance in EGFR (搜索)-mutant non-small cell lung cancer by combining EGFR and c-MET (搜索) pathway inhibition.
CL-273 (搜索) offers a 4-5 fold wider therapeutic window than existing therapies due to its wild-type-sparing profile, while CL-741 (搜索) is Phase 1-ready for c-MET (搜索)-driven solid tumors.
Kairos Pharma (搜索), Ltd. has signed a term sheet for the strategic acquisition of two clinical-stage oncology assets from privately held Celyn Therapeutics (搜索), Inc., marking a significant expansion of the company's lung cancer pipeline. The transaction will bring CL-273 (搜索), a pre-IND reversible pan-EGFR (搜索) inhibitor, and CL-741 (搜索), a Phase 1-ready c-MET (搜索) kinase inhibitor, into Kairos's portfolio targeting non-small cell lung cancer (NSCLC).
Strategic Focus on Resistance Mechanisms
The acquisition aligns with Kairos Pharma (搜索)'s core strategy of tackling resistance mechanisms that emerge in patients with EGFR (搜索)-mutant NSCLC. According to John Yu, M.D., Kairos Pharma Chief Executive Officer, "We anticipate this acquisition will significantly expand our oncology pipeline with late-preclinical and Phase 1-ready assets in a multi-billion dollar market with substantial unmet medical needs."
MET amplification represents one of the most important resistance mechanisms in EGFR (搜索)-mutant NSCLC. The company believes that combining a pan-EGFR inhibitor with a c-MET (搜索) inhibitor provides a compelling and well-validated clinical approach. Dual inhibition of EGFR and MET pathways can overcome compensatory signaling that drives resistance, deepens tumor responses, and extends progression-free survival in this difficult-to-treat patient population.
Market Opportunity and Clinical Rationale
The kinase inhibitor market for cancer treatment was valued at $60.7 billion in 2025, with EGFR (搜索) inhibitors representing 32.5% of this market. CL-273 (搜索) targets the EGFR mutated lung cancer treatment market, valued at $16.2 billion in 2026. EGFR mutations are present in approximately 10-15% of NSCLC cases in Western populations and up to 50% in Asian populations, creating a substantial addressable patient population.
The c-MET (搜索) inhibitor market is experiencing rapid growth, valued at more than $2 billion and projected to reach over $10 billion by 2030 with a compound annual growth rate exceeding 17%. Clinical studies have demonstrated that combination treatment with EGFR (搜索) and MET inhibitors for EGFR-mutant, MET-amplified NSCLC patients can achieve progression-free survival of approximately 7 months, representing a significant advance over single-agent therapy as shown in the SAVANNAH trial.
Asset Profiles and Differentiation
CL-273: Wild-Type-Sparing Pan-EGFR Inhibitor
CL-273 (搜索) is an investigational, reversible, wild-type-sparing pan-EGFR (搜索) small-molecule inhibitor specifically engineered for EGFR-mutant NSCLC. Preclinical data demonstrate broad-spectrum activity against classical EGFR mutations including Exon 19 and 21 deletions and Exon 20 insertions, atypical mutations, and resistance-associated variants that bypass currently approved tyrosine kinase inhibitors.
A defining feature of CL-273 (搜索) is its exceptional selectivity index. By sparing wild-type EGFR (搜索), studies have shown CL-273 offers a 4-5 fold wider therapeutic window, suggesting significantly improved safety and tolerability over existing therapies. The compound is designed for high brain and lung permeability to address metastatic disease and has successfully completed GLP toxicology studies. First-in-human clinical trials are projected to commence in 2026.
CL-741: Selective c-MET Kinase Inhibitor
CL-741 (搜索) is an orally available, small-molecule, type IIb c-MET (搜索) kinase inhibitor designed to be highly selective for c-MET with broad coverage of activating and acquired resistance mutations in solid tumors. The compound demonstrates potent activity across multiple c-MET resistance mutants and is being developed for c-MET-driven advanced solid tumors, with primary focus on NSCLC harboring MET exon 14 skipping alterations and MET amplification.
AI-Driven Discovery Platform
Nikolay Savchuk, Ph.D., CEO of Celyn Therapeutics (搜索), highlighted the role of artificial intelligence in the discovery process: "Our proprietary AI-driven drug design platform has enabled the discovery of a highly efficacious, wild-type-sparing, pan-mutant EGFR (搜索) inhibitor. This molecule offers a 4-to-5-fold broader safety margin than current competitive inhibitors."
Celyn was founded in 2021 with backing from OrbiMed (搜索) and Torrey Pines Investment (搜索), operating largely under the radar. The company utilized AI-focused companies Molsoft and Chemdiv in the discovery of its inhibitors.
Clinical Infrastructure and Development Plans
Kairos Pharma (搜索)'s established clinical consortia on the West Coast, anchored at Cedars-Sinai Medical Center in Los Angeles, provides the clinical infrastructure and expertise to rapidly initiate and execute Phase 1 and Phase 2 studies for both compounds. The acquisition of both assets is anticipated to enable Kairos to pursue a differentiated dual-target strategy addressing both primary EGFR (搜索) mutations and MET-mediated resistance mechanisms.
Transaction Timeline and Financial Considerations
The potential tie-up is currently the subject of a term sheet, with Kairos indicating that a formal deal is expected to close within three months. However, the company declined to disclose financial terms of the transaction.
Kairos faces financial constraints that might limit its ambitions, with the company reporting just $5 million in cash as of November 2025, projecting a runway into late 2026. This projection might be shorter following the acquisition, with further clarity expected when Kairos reports its first-quarter results.
Integration with Existing Pipeline
The acquired assets might ultimately fit alongside Kairos's lead programme, carotuximab (ENV-105), an anti-CD105 (搜索) monoclonal antibody currently in Phase 2 clinical trials for castrate-resistant prostate cancer and Phase 1 trials for NSCLC. CD105 is expressed on lung tumors and is believed to contribute to resistance against EGFR (搜索) inhibitors.
If ongoing trials with carotuximab in combination with Tagrisso show positive results, Kairos could potentially incorporate the antibody into combinations with the newly acquired EGFR (搜索) and c-MET (搜索) inhibitors, creating a comprehensive approach to overcoming multiple resistance mechanisms in lung cancer.